Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LEF1 | Q9UJU2 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 7/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | PYGL | P06737 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 7/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PRNP | P04156 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PLD2 | O14939 | 1/20 | 0.43 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GUSB | P08236 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7155166 | 0.89 | HRH4 (0.55) | KDM4EHRH4RAB9ANPC1ALDH1A1 | |
| SCHEMBL5896864 | 0.86 | LEF1 (0.51) | LEF1KDM4EHRH4MMP13RAB9A | |
| SCHEMBL5087401 | 0.85 | MMP13 (0.65) | KDM4EMMP13RAB9ATP53PYGL | |
| SCHEMBL28082015 | 0.84 | MAOA (0.59) | KDM4EHRH4RAB9ATP53PYGL | |
| SCHEMBL931628 | 0.83 | NHERF1 (0.52) | HRH4RAB9ATP53PYGLNPC1 | |
| SCHEMBL5087408 | 0.83 | LEF1 (0.59) | LEF1KDM4EMMP13RAB9ATP53 | |
| SCHEMBL23258395 | 0.82 | MEN1 (0.57) | KDM4EHRH4RAB9ATP53NPC1 | |
| SCHEMBL9524229 | 0.81 | LEF1 (0.53) | LEF1KDM4EHRH4MMP13RAB9A | |
| SCHEMBL6177517 | 0.81 | MAPT (0.42) | LEF1HRH4RAB9ANPC1ALDH1A1 | |
| SCHEMBL3497422 | 0.81 | EGFR (0.57) | LEF1KDM4EMMP13RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329760-B2 | CC-1065 analog synthesis | IMMUNOGEN INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1492766-B1 | IMPROVED CC-1065 ANALOG SYNTHESIS | IMMUNOGEN INC (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1492766-B1 | IMPROVED CC-1065 ANALOG SYNTHESIS | IMMUNOGEN INC (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1492766-A4 | IMPROVED CC-1065 ANALOG SYNTHESIS | IMMUNOGEN INC (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1492766-A1 | IMPROVED CC-1065 ANALOG SYNTHESIS | Immunogen, Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003087055-A1 | IMPROVED CC-1065 ANALOG SYNTHESIS | IMMUNOGEN, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030195365-A1 | CC-1065 analog synthesis | IMMUNOGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-6534660-B1 | Halogenation, alkylation and ring-closure of protected 2-amino-4-hydroxynaphthalene under suitable conditions to provide desired racemate, isolating (-) isomer, removing protecting groups | IMMUNOGEN, INC. | 2003-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195365-A1 | CC-1065 analog synthesis | DCUN1D5, DCUN1D1, DBN1 | LEF1 1682/4885KDM4E 682/4885HRH4 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.